Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Bailard Inc.

Bailard Inc. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 46,856 shares of the medical research company’s stock after purchasing an additional 1,243 shares during the quarter. Bailard Inc.’s holdings in Amgen were worth $13,495,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in AMGN. OFI Invest Asset Management bought a new position in shares of Amgen during the third quarter valued at approximately $26,000. Briaud Financial Planning Inc bought a new position in shares of Amgen during the third quarter valued at approximately $26,000. BOK Financial Private Wealth Inc. bought a new position in shares of Amgen during the fourth quarter valued at approximately $29,000. Providence Capital Advisors LLC bought a new position in shares of Amgen during the third quarter valued at approximately $30,000. Finally, Planned Solutions Inc. bought a new position in Amgen in the 4th quarter worth approximately $30,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Down 0.2 %

Shares of NASDAQ AMGN traded down $0.53 during mid-day trading on Wednesday, reaching $273.01. The company had a trading volume of 2,466,582 shares, compared to its average volume of 2,840,533. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a market capitalization of $146.44 billion, a PE ratio of 21.86, a price-to-earnings-growth ratio of 2.53 and a beta of 0.58. The stock’s 50 day moving average is $275.77 and its 200-day moving average is $281.55.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same period in the prior year, the business posted $4.09 earnings per share. Amgen’s revenue for the quarter was up 19.8% compared to the same quarter last year. As a group, equities analysts anticipate that Amgen Inc. will post 19.45 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.30%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

Analyst Ratings Changes

AMGN has been the subject of a number of recent analyst reports. Leerink Partnrs lowered Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $329.00 price objective on shares of Amgen in a report on Wednesday, April 3rd. TD Cowen decreased their price objective on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Oppenheimer reissued an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a report on Thursday, February 1st. Finally, StockNews.com lowered Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and an average price target of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.